[Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension].

Objective: To investigate blood pressure-lowering effect of rosiglitazone in overweight/obese non-diabetic patients with hypertension to explore the therapeutic role of insulin sensitizers in the management of essential hypertension.

Methods: 89 cases of overweight/obese non-diabetics with essential hypertension were enrolled in a 4 weeks open label clinical trial. Rosiglitazone 8 mg/day were started 2 weeks after withdrawing previously used anti-hypertensive medications.

[Clinical study on relationship between sluggishness of lung-defensive qi and levels of vasoactive intestinal polypeptide and thromboxane B2].

Objective: To explore the nature of pathology of sluggishness of lung-defensive qi and to offer objective experimental indexes for weifen syndrome (defensive phase syndrome).

Methods: According to the completely random design, the plasma levels of vasoactive intestinal peptide (VIP) and thromboxane B2 (TX2) of 19 patients with weifen syndrome and 13 patients with qifen syndrome (qi phase syndrome) were detected by radioimmunoassay. The plasma levels of VIP and TX2 at different stages of weifen syndrome and qifen syndrome were observed.